Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells

Autor: T Haimowitz, Arnone, SK Chunduru, GS Kapoor, Y Mitsuuchi, CG Begley, SC Beck, ME Seipel, Y Deng, SM Condon, CA Benetatos, MA McKinlay

Publikováno v: Cell Death Discovery

The inhibitor of apoptosis (IAP) proteins have pivotal roles in cell proliferation and differentiation, and antagonizing IAPs in certain cancer cell lines results in induction of cell death. A variety of IAP antagonist compounds targeting the baculov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b760e7bc7de64e5935eefe0ef26fbd95
http://europepmc.org/articles/PMC5238498

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.

Autor: Nishihori T; Moffitt Cancer Center, Tampa, FL., Hoffman JE; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL., Huff A; GlaxoSmithKline, Collegeville, PA., Kapoor GS; GlaxoSmithKline, Collegeville, PA., Eleftheriadou I; GlaxoSmithKline, Collegeville, PA., Zajic S; GlaxoSmithKline, Collegeville, PA., Urbano A; GlaxoSmithKline, Collegeville, PA., Suchindran S; GlaxoSmithKline, Collegeville, PA., Chisamore M; Merck & Co, Inc, Rahway, NJ., D'Souza JW; GlaxoSmithKline, Collegeville, PA., Faitg T; GlaxoSmithKline, Collegeville, PA., Rapoport AP; University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD.

Publikováno v: Blood advances [Blood Adv] 2023 Apr 11; Vol. 7 (7), pp. 1168-1177.

Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.

Autor: Walsh AM; Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania., Kapoor GS; Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania., Buonato JM; Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania., Mathew LK; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania. Howared Hughes Medical Institute, University of Pennsylvania, Philadelphia, Pennsylvania., Bi Y; Center for Systems and Computational Biology, Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania., Davuluri RV; Center for Systems and Computational Biology, Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania., Martinez-Lage M; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Simon MC; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania. Howared Hughes Medical Institute, University of Pennsylvania, Philadelphia, Pennsylvania., O'Rourke DM; Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Lazzara MJ; Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania. Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania. mlazzara@seas.upenn.edu.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2015 Aug; Vol. 13 (8), pp. 1227-37. Date of Electronic Publication: 2015 May 01.

Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Autor: Benetatos CA; Authors' Affiliations: TetraLogic Pharmaceuticals, 343 Phoenixville Pike, Malvern, Pennsylvania; and Tsinghua University School of Medicine, Beijing, China., Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Apr; Vol. 13 (4), pp. 867-79. Date of Electronic Publication: 2014 Feb 21.

Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

Autor: Tykocinski ES; Departments of Neurosurgery, Hospital of The University of Pennsylvania and The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA., Grant RA, Kapoor GS, Krejza J, Bohman LE, Gocke TA, Chawla S, Halpern CH, Lopinto J, Melhem ER, O'Rourke DM

Publikováno v: Neuro-oncology [Neuro Oncol] 2012 May; Vol. 14 (5), pp. 613-23. Date of Electronic Publication: 2012 Apr 04.